Arcus Biosciences
RCUS
142 hedge funds and large institutions have $2.06B invested in Arcus Biosciences in 2021 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 47 increasing their positions, 48 reducing their positions, and 20 closing their positions.
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
22% more capital invested
Capital invested by funds: $1.68B → $2.06B (+$373M)
8% more funds holding
Funds holding: 131 → 142 (+11)
4.74% more ownership
Funds ownership: 67.62% → 72.35% (+4.7%)
2% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 48
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
35% less call options, than puts
Call options by funds: $6.08M | Put options by funds: $9.31M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$50.5M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$43.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37.2M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$15.6M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$14.4M |
Top Sellers
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
-$59.6M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$25.3M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$17.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$10.6M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$10.4M |
RCUS Hedge Fund Activity: Q4 2021 in Review
142 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2021, worth a combined $2.06B — up 22% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new RCUS positions and 20 closed out — a net gain of 12 holders — while 47 added to existing stakes and 48 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $50.5M. The largest seller was Alphabet Inc, cutting an estimated $59.6M.
- 142 institutional investors held Arcus Biosciences (RCUS) as of Q4 2021, up from 131 in Q3 2021.
- Funds reported $2.06B of Arcus Biosciences stock for Q4 2021, up 22% quarter-over-quarter.
- 32 funds opened new Arcus Biosciences positions in Q4 2021 and 20 closed out, a net change of +12 holders.
- The largest Arcus Biosciences buyer in Q4 2021 was Morgan Stanley, an estimated $50.5M added.
- The largest Arcus Biosciences seller in Q4 2021 was Alphabet Inc, an estimated $59.6M sold.
Based on aggregated 13F filings for Q4 2021.